Biotech Stocks Reviews
- MDNA Reports First Response in IL-2 Program
Wed, Sep 28
Medicenna (MDNA) confirmed the partial response (PR) that the Company previously reported from their · more » - Astria Sees Early Run Ahead of Phase 1 Data
Tue, Sep 20
Astria (ATXS) is up 135% since we bought a position in early August under $4/share. The Company · more » - Taking Profits Ahead of MIST Data
Mon, Sep 19
We bought Milestone Pharma (MIST) just over a month ago under $7/share to play the topline Phase 3 data · more » - A Look At AFMD Ahead of Q4 2022 Catalysts
Tue, Aug 16
Affimed gave a Q2 2022 business update which was mixed. Their second half is expected to have a few · more » - Medicenna Halts Momentum With Financing
Tue, Aug 9
This morning Medicenna (MDNA)announcedthe pricing of a $20M financing. 13.33M shares were sold at · more » - Milestone Pharma Attractive Ahead of Phase 3 Data
Mon, Aug 8
The XBI is seeing life as MA activity is picking up. Last week Amgen acquired ChemoCentryx (CCXI) for · more » - Astria Clears IND. On pace for YE2022 Data
Mon, Aug 1
Astria (ATXS) announced the FDA clearance of their IND application for STAR-0215 for hereditary · more » - MDNA11 Continues Reporting Positive Updates, Although No Response Yet
Thu, Jul 28
A story that is developing which could impact the whole bio industry is ahealthcare billmaking noise in · more » - Watchlist Heading into 2H 2022
Mon, Jul 11
The biotech market saw the total EV of publicly traded companies continue to rise to start July, up by · more »